ImmunityBio announces database lock for registrational trial of ANKTIVA plus BCG in bladder cancer
IBRX•ImmunityBio said the registrational trial of locally delivered ANKTIVA plus BCG in BCG-naïve non-muscle invasive bladder cancer has reached database lock. Final analysis is underway, with topline results expected in November 2026; the company is on track to submit a supplemental biologics license application in the fourth quarter of 2026.
1. Trial analysis underway
ImmunityBio announced database lock for its registrational trial of locally delivered, chemotherapy-free ANKTIVA plus BCG in BCG-naïve non-muscle invasive bladder cancer. The company said final analysis is underway and topline results are expected in November 2026.
2. Filing timeline
ImmunityBio said it is on track to submit a supplemental biologics license application for ANKTIVA plus BCG in the fourth quarter of 2026. An interim analysis showed longer complete response with ANKTIVA plus BCG versus BCG alone.
